US FDA Rejects Lilly’s Bid For Donanemab Accelerated Approval In Early Alzheimer’s

Eisai/Biogen’s Leqembi Remains Lone Anti-Amyloid In US

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.